Breaking News Instant updates and real-time market news.

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23

Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes

Amgen announced new data that show Repatha, or evolocumab, significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha, in lowering LDL-C and improving other lipid levels in patients with Type 2 diabetes. In addition to meeting criteria for hypercholesterolemia or mixed dyslipidemia, patients in the trial had varying degrees of glycemic control. Data were presented at the American Diabetes Association 78th Annual Scientific Sessions. Results from the BANTING study show that in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, the addition of Repatha to background statin therapy resulted in significant reductions in LDL-C levels. Type 2 diabetes is often associated with dyslipidemia, a condition characterized by low "good" cholesterol or HDL-C and elevated "bad" cholesterol or LDL-C. In addition to producing significant reductions in LDL-C levels, the addition of Repatha to background statin therapy enabled most patients to reach LDL-C levels recommended by current guidelines. The majority of patients in the Repatha group reached LDL-C levels of less than70 mg/dL as recommended by the American College of Clinical Endocrinologists for patients with Type 2 diabetes and one or more risk factors. Treatment with Repatha was also associated with a significantly higher percentage of patients achieving the greater than or equal to 50% reduction in LDL-C levels recommended by the American College of Cardiology and the American Heart Association. Repatha also reduced several other lipid parameters, including non-HDL-C. These results are consistent with results from previous Phase 3 studies demonstrating Repatha's efficacy in reducing LDL-C and non-HDL-C levels in patients with Type 2 diabetes independent of glycemia, insulin use, renal function and cardiovascular disease status at baseline. The safety profile in BANTING was consistent with the established safety profile of Repatha.

AMGN Amgen
$184.86

-1.14 (-0.61%)

06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/22/18
MSCO
06/22/18
NO CHANGE
Target $200
MSCO
Overweight
Amgen may be pressured by IMS restatement for Aimovig, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that IMS announced that it has overstated the mail order volume for Amgen's Aimovig and will amend its mail order method with this week's data and restate prior weeks next Friday. Preliminary figures indicate the restatement will lower overall total prescriptions by about 27%, said Harrison. He would expect pressure on Amgen shares given the perception negative, though he still thinks initial Aimovig demand is robust, Harrison tells investors. He keeps an Overweight rating and $200 price target on Amgen shares.

TODAY'S FREE FLY STORIES

VZ

Verizon

$53.53

-0.07 (-0.13%)

, S

Sprint

$6.38

0.1 (1.59%)

15:25
10/16/18
10/16
15:25
10/16/18
15:25
Hot Stocks
FCC calls on wireless cos to waive bills of Floridians affected by hurricane »

Federal Communications…

VZ

Verizon

$53.53

-0.07 (-0.13%)

S

Sprint

$6.38

0.1 (1.59%)

TMUS

T-Mobile

$68.72

1.1 (1.63%)

USM

U.S. Cellular

$48.55

0.62 (1.29%)

T

AT&T

$32.39

0.03 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 02

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

BLK

BlackRock

$404.72

-22.68 (-5.31%)

15:21
10/16/18
10/16
15:21
10/16/18
15:21
Recommendations
BlackRock analyst commentary  »

BlackRock weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

VRSK

Verisk Analytics

$115.81

2.5 (2.21%)

15:20
10/16/18
10/16
15:20
10/16/18
15:20
Hot Stocks
Geomni forms strategic alliance with Skyline Software Systems »

Geomni, a Verisk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

OSTK

Overstock.com

$26.96

0.18 (0.67%)

15:19
10/16/18
10/16
15:19
10/16/18
15:19
Hot Stocks
Overstock announces completion of issuance of preferred tZERO security tokens »

tZERO, a portfolio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$72.25

1.39 (1.96%)

15:19
10/16/18
10/16
15:19
10/16/18
15:19
Options
CSX options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

FCB

FCB Financial

$43.96

-0.69 (-1.55%)

15:17
10/16/18
10/16
15:17
10/16/18
15:17
Hot Stocks
FCB does not see material adverse portfolio impact from Hurricane Michael »

FCB Financial reports it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/16/18
10/16
15:17
10/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/16/18
10/16
15:16
10/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
10/16/18
10/16
15:05
10/16/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MAXR

Maxar Technologies

$30.30

0.89 (3.03%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Hot Stocks
Maxar's MDA ships final spacecraft in preparation for RADARSAT mission »

MDA, a Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$144.76

3.64 (2.58%)

15:04
10/16/18
10/16
15:04
10/16/18
15:04
Options
IBM options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

BA

Boeing

$367.17

8.36 (2.33%)

15:02
10/16/18
10/16
15:02
10/16/18
15:02
Hot Stocks
Boeing sees air cargo traffic doubling in 20 years »

Boeing projects air cargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 24

    Oct

CLDR

Cloudera

$15.68

0.44 (2.89%)

15:01
10/16/18
10/16
15:01
10/16/18
15:01
Hot Stocks
Cloudera announces strategic alliance with NEC »

Cloudera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MNKD

MannKind

$1.90

0.24 (14.46%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Hot Stocks
FDA sends warning letter to MannKind over Affrezza marketing »

In a warning letter sent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.93

1.44 (3.10%)

15:00
10/16/18
10/16
15:00
10/16/18
15:00
Options
Call spread in Crown Holdings in front of earnings »

Call spread in Crown…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

, JPM

JPMorgan

$108.59

2.25 (2.12%)

14:55
10/16/18
10/16
14:55
10/16/18
14:55
Recommendations
On Deck Capital, JPMorgan analyst commentary  »

Janney Montgomery Scott…

ONDK

On Deck Capital

$7.28

0.51 (7.53%)

JPM

JPMorgan

$108.59

2.25 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 06

    Nov

  • 26

    Feb

OSTK

Overstock.com

$27.11

0.33 (1.23%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Hot Stocks
Overstock.com says Customer Day 'strongest' non-Holiday sale in company history »

Overstock.com reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$60.29

1.36 (2.31%)

14:50
10/16/18
10/16
14:50
10/16/18
14:50
Options
DowDuPont draws call buyers »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$341.60

8.49 (2.55%)

14:49
10/16/18
10/16
14:49
10/16/18
14:49
Options
Netflix options imply 14.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 13

    Nov

14:45
10/16/18
10/16
14:45
10/16/18
14:45
General news
Canada Manufacturing Preview »

Canada Manufacturing…

H

Hyatt

$72.79

1.08 (1.51%)

14:42
10/16/18
10/16
14:42
10/16/18
14:42
Recommendations
Hyatt analyst commentary  »

Hyatt to-be-acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ALLY

Ally Financial

$25.87

-0.22 (-0.84%)

14:40
10/16/18
10/16
14:40
10/16/18
14:40
Options
Ally Financial attracts put buying as shares see relative weakness »

Ally Financial attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CDNS

Cadence Design

$40.13

0.74 (1.88%)

14:34
10/16/18
10/16
14:34
10/16/18
14:34
Hot Stocks
Cadence Design says Verification Suite enabled for HPC server environments »

Cadence Design Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

EEM

iShares MSCI Emerging Markets ETF

$40.79

0.95 (2.38%)

14:30
10/16/18
10/16
14:30
10/16/18
14:30
Options
Aggressive call spread opened in iShares Emerging Markets Fund »

Aggressive call spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$36.25

3.81 (11.74%)

14:25
10/16/18
10/16
14:25
10/16/18
14:25
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.